Pelvic radiotherapy versus radical prostatectomy with limited lymph node sampling for high-grade prostate adenocarcinoma

Christopher B. Baker, Andrew M. McDonald, Eddy S. Yang, Rojymon Jacob, Soroush Rais-Bahrami, Jeffrey W. Nix, John B. Fiveash

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Purpose. To compare oncologic outcomes for patients with Gleason score (GS) ≥ 8 prostate adenocarcinoma treated with radical prostatectomy (RP) versus external beam radiotherapy combined with androgen deprivation (RT + ADT). Methods. Between 2001 and 2014, 121 patients with GS ≥ 8 were treated at our institution via RT + ADT (n = 71) or RP (n = 50) with ≥ 1 year of biochemical follow-up. Endpoints included biochemical failure (BF), distant metastasis, and initiation of salvage ADT. Results. The RT + ADT group was older, had higher biopsy GS, and had greater risk of lymph node involvement. All other pretreatment characteristics were similar between groups. Mean number of lymph nodes (LNs) sampled for patients undergoing RP was 8.2 (±6.18). Mean biochemical follow-up for all patients was 61 months. Five-year estimates of BF for the RT + ADT and RP groups were 7.2% versus 42.3%, (p < 0.001). The RT + ADT group also had lower rates of distant metastasis (2% versus 7.8%) and salvage ADT (8% versus 33.8%). Conclusion. In this analysis, RT + ADT was associated with improved biochemical and metastatic control when compared to RP with limited LN sampling. How RT + ADT compares with more aggressive lymphadenectomy, as is currently our institutional standard, remains an important unanswered question.

Original languageEnglish
Article number2674954
JournalProstate Cancer
Volume2016
DOIs
StatePublished - 2016

Bibliographical note

Publisher Copyright:
© 2016 Christopher B. Baker et al.

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Pelvic radiotherapy versus radical prostatectomy with limited lymph node sampling for high-grade prostate adenocarcinoma'. Together they form a unique fingerprint.

Cite this